highperformr logo

Syndax Pharmaceuticals's Overview

Total employees286
HeadquartersWaltham
Founded

Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with cancer. Their pipeline is built on two core platforms: an inhibitor of the Menin-MLL interaction, revumenib (SNDX-5613), and an anti-CSF-1R antibody, axatilimab (SNDX-6352). These candidates target oncogenic pathways and modulate the tumor microenvironment, respectively, with the goal of addressing unmet medical needs in various hematologic malignancies and solid tumors. Syndax is dedicated to advancing its drug candidates through rigorous clinical trials to bring meaningful new treatments to cancer patients.

Where is Syndax Pharmaceuticals's Headquarters?

Syndax Pharmaceuticals officeSyndax Pharmaceuticals officeSyndax Pharmaceuticals officeSyndax Pharmaceuticals office
*Images sourced via web search. Rights belong to original owners

HQ Function

The Waltham headquarters serves as the central nexus for Syndax's corporate strategy, research and development oversight, clinical operations management, financial activities, and business development efforts.

Notable Features:

Located within a modern office park that caters to life science companies, offering facilities conducive to collaboration and scientific advancement.

Work Culture:

The work culture at Syndax is characterized by a strong scientific focus, collaborative teamwork, and a patient-centric mission. Employees are driven by the pursuit of innovative cancer therapies and a commitment to making a difference in patients' lives.

HQ Significance:

Its location in the Boston-Cambridge biotech cluster provides strategic advantages, including access to a rich talent pool, world-class research institutions, and a vibrant network of potential collaborators and service providers.

Values Reflected in HQ: The headquarters' environment likely reflects Syndax's core values of scientific rigor, innovation, collaboration, and urgency in addressing patient needs.

Location:

While Syndax Pharmaceuticals is headquartered in the United States, its operational reach is global, primarily through the execution of clinical trials. The company collaborates with clinical research organizations (CROs), investigators, and trial sites in North America, Europe, and other regions as necessary to advance its pipeline of cancer therapies. This global approach is essential for recruiting diverse patient populations and navigating multinational regulatory pathways for drug development.

Street Address:

35 Gatehouse Drive, Building D, Floor 3

City:

Waltham

State/Province:

MA

Country:

USA

Syndax Pharmaceuticals's Global Presence

Buying Intent Signals for Syndax Pharmaceuticals

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Syndax Pharmaceuticals

As of April 2025, Syndax Pharmaceuticals' leadership includes:

Michael A. Metzger - Chief Executive Officer
Briggs W. Morrison, M.D. - President, Head of Research & Development
Keith A. Goldan - Chief Financial Officer
Neil Gallagher, M.D., Ph.D. - Chief Medical Officer
Jennifer J. Freeman, J.D., M.P.H. - Chief Business Officer
Luke J. Albrecht, M.S. - Chief Accounting Officer
John P. DePersico, J.D. - General Counsel and Corporate Secretary

Investors of Syndax Pharmaceuticals

Syndax Pharmaceuticals has been backed by several prominent investors over the years, including:

RA Capital Management
BlackRock Inc.
The Vanguard Group, Inc.
Biotechnology Value Fund, L.P.
EcoR1 Capital, LLC
State Street Global Advisors
Fidelity Management & Research Company (FMRCo)

Executive New Hires/Exits in the Last 12 Months

Hire2
Exits0

Syndax Pharmaceuticals has focused on strengthening its leadership team, particularly in commercial and financial roles, reflecting its progress towards potential commercialization. Key appointments have been made to bolster these functions.

New Appointments:

Neil Gallagher, M.D., Ph.D., Dr. Neil Gallagher joined Syndax as Chief Medical Officer, enhancing the company's clinical development leadership.
Luke J. Albrecht, M.S., Luke J. Albrecht was appointed Chief Accounting Officer, responsible for all accounting operations and financial reporting.

Technology (Tech Stack) used by Syndax Pharmaceuticals

Discover the tools Syndax Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Syndax Pharmaceuticals Email Formats and Examples

Syndax Pharmaceuticals likely utilizes common corporate email patterns, typically combining an employee's first initial and last name, or first name and last name separated by a dot.

[first_initial][last]@syndax.com

Format

mmetzger@syndax.com

Example

80%

Success rate

News and media

Syndax Pharmaceuticals Press ReleaseMay 29, 2024

Syndax to Present Updated Data from the Revumenib Menin Inhibitor Program at the European Hematology Association (EHA) 2024 Hybrid Congress

Syndax announced it will present updated data from its revumenib clinical trials, including the BEAT-AML and AUGMENT-101 studies, at the upcoming EHA2024 Congress. These presentations will highlight efficacy and safety in patients with relapsed/refractory acute leukemias....more

Syndax Pharmaceuticals Press ReleaseMay 7, 2024

Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Syndax reported its Q1 2024 financial results, detailing its cash position and operational progress. Key updates included advancements in the revumenib and axatilimab programs, with expectations for NDA submission for revumenib and pivotal trial initiation for axatilimab in cGVHD....more

Syndax Pharmaceuticals Press ReleaseApril 2, 2024

Syndax to Present New Data from Axatilimab and Revumenib Programs at the AACR Annual Meeting 2024

Syndax announced presentations of new preclinical and clinical data for both axatilimab and revumenib at the American Association for Cancer Research (AACR) Annual Meeting 2024, further showcasing the potential of its pipeline....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Syndax Pharmaceuticals, are just a search away.